文献速递流行病学与生物统计基础与转化研究

利用结局间关系的贝叶斯多变量网状Meta分析及其在复发缓解型多发性硬化中的应用

Exploiting relationships between outcomes in Bayesian multivariate network meta-analysis with an application to relapsing-remitting multiple sclerosis.
PubMed 文献 · Stat Med · 2020-07-16

针对多变量网状Meta分析中部分治疗-结局组合无直接证据的问题,提出一种贝叶斯多变量NMA模型,通过人群平均效应间的映射估计缺失组合,并允许研究间效应不完全相关。将该模型应用于复发缓解型多发性硬化的8种活性治疗,同时评估疗效与肝脏安全性,结果显示芬戈莫德和干扰素β-1b疗效最佳但肝脏安全性较差,富马酸二甲酯和醋酸格拉替雷在疗效与安全性上表现均衡。

要点

  • 贝叶斯多变量NMA可估计缺失治疗-结局组合,允许研究间效应不完全相关。
  • 芬戈莫德和干扰素β-1b疗效最佳但肝脏安全性较差。
  • 富马酸二甲酯和醋酸格拉替雷在疗效与安全性结局上表现均衡。

核心结论

  • 所提出的贝叶斯多变量NMA模型可通过结局间映射估计缺失的治疗-结局组合,并允许研究间效应不完全相关。
  • 在复发缓解型多发性硬化中,芬戈莫德和干扰素β-1b疗效最佳但肝脏安全性较差,富马酸二甲酯和醋酸格拉替雷在疗效与安全性上表现均衡。

研究设计与样本

  • 方法学研究:提出贝叶斯多变量网状Meta分析模型,适用于聚合水平数据。
  • 通过治疗效应方差的新分解实现模型,可针对任意数据集高效指定。
  • 应用于复发缓解型多发性硬化的8种活性治疗的疗效与肝脏安全性数据。

主要发现

  • 模型可估计缺失的治疗-结局组合,无需假设结局间完全相关或效应大小恒定。
  • 芬戈莫德和干扰素β-1b是最有效的治疗,但对肝脏安全性的影响也最差。
  • 富马酸二甲酯和醋酸格拉替雷在模型的所有疗效与安全性结局上表现合理。

临床怎么用

  • 当多个结局报告稀疏或同一结局采用不同定义时,可考虑使用该多变量NMA模型进行证据合成。
  • 在复发缓解型多发性硬化治疗选择中,需权衡疗效与肝脏安全性,芬戈莫德和干扰素β-1b疗效好但肝脏安全性较差。

局限性

  • 方法针对聚合水平数据设计,而非个体患者数据。
  • 模型指定需对相关结构作出基本假设。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In multivariate network meta-analysis (NMA), the piecemeal nature of the evidence base means that there may be treatment-outcome combinations for which no data is available. Most existing multivariate evidence synthesis models are either unable to estimate the missing treatment-outcome combinations, or can only do so under particularly strong assumptions, such as perfect between-study correlations between outcomes or constant effect size across outcomes. Many existing implementations are also limited to two treatments or two outcomes, or rely on model specification that is heavily tailored to the dimensions of the dataset. We present a Bayesian multivariate NMA model that estimates the missing treatment-outcome combinations via mappings between the population mean effects, while allowing the study-specific effects to be imperfectly correlated. The method is designed for aggregate-level data (rather than individual patient data) and is likely to be useful when modeling multiple sparsely reported outcomes, or when varying definitions of the same underlying outcome are adopted by different studies. We implement the model via a novel decomposition of the treatment effect variance, which can be specified efficiently for an arbitrary dataset given some basic assumptions regarding the correlation structure. The method is illustrated using data concerning the efficacy and liver-related safety of eight active treatments for relapsing-remitting multiple sclerosis. The results indicate that fingolimod and interferon beta-1b are the most efficacious treatments but also have some of the worst effects on liver safety. Dimethyl fumarate and glatiramer acetate perform reasonably on all of the efficacy and safety outcomes in the model.

来源:Stat Med,查看原文。版权归原作者所有。

引用

  1. Waddingham E, Matthews PM, Ashby D, et al. Exploiting relationships between outcomes in Bayesian multivariate network meta-analysis with an application to relapsing-remitting multiple sclerosis. Stat Med. 2020. PMID: 32672370. doi:10.1002/sim.8668

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。